115.6604.86% ( +5.360 )
Closed: Nov 13, 16:00:00 (EDT)Valuation
Current ValuationThe current P/E ratio is -22.30, within the reasonable range, cheaper than 64.72% of the time in the past 5 years, and the industry ranks 54/74, the industry Median 0.25.
-22.3xP/E
$115.66Stock price
$-5.19Earnings per share
-22.3xP/E
Stock price$115.66Earnings per share$-5.19
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -8.92x
- Typical range
- -78.16x–-3.47x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 0.25x
08162432
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 0.25x
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GHUSGuardant Health | -41.97x | 1.58% | $20.36B |
RDNTUSRadnet | -268.99x | 54.67% | $6.02B |
HIMSUSHims & Hers Health | -24.23x | 277.51% | $4.62B |
NEOUSNeogenomics | -64.18x | 71.60% | $2.07B |
AGLUSagilon health | -22.30x | 108.89% | $1.94B |
WGSUSGeneDx | -14.13x | 355.82% | $1.57B |
LMRIUSLumexa Imaging | -83.49x | 160.23% | $1.42B |
OPKUSOpko Health | -8.43x | 26.12% | $1.25B |
CSTLUSCastle Biosciences | -45.25x | 1.20% | $1.04B |
AONCUSAmerican Oncology Network | -- | -- | $779.39M |
FLGTUSFulgent Genetics | -7.58x | 42.64% | $688.98M |
SRTAUSStrata Critical Medical | -19.65x | 34.38% | $487.45M |
PREUSPrenetics Global | -6.02x | 11.12% | $283.04M |
GAMGUSGlobal Asset Management Group, Inc. | -296.90x | -- | $167.58M |
CORBFUSGlobal Cord Blood Corporation | -- | -- | $129.90M |
BDSXUSBiodesix | -4.05x | 38.44% | $109.55M |
PARKUSPark Dental Partners | -28.91x | -- | $102.19M |
NAKAUSNakamoto | -0.21x | 102.50% | $89.47M |
AIRSUSAirSculpt Tech | -6.58x | 9.21% | $61.88M |
EUDAUSEuda Health | -19.70x | 208.11% | $46.56M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
